Smarter. Stronger. Together. Expert Guidance, Tools, and Resources to Optimize the Care of Patients With HER2-Negative Early-Stage Breast Cancer

Get up to date on the multidisciplinary care of patients with HER2-negative early-stage breast cancer with this comprehensive educational program featuring Medical Minute modules, downloadable slides, topical commentaries, a patient resource, and an interactive decision support tool providing case-specific treatment recommendations from an expert panel.

Share

Program Content

Activities

Challenges for HER2neg EBC
Current Challenges With Individualizing Therapy for HER2-Negative Early-Stage Breast Cancer
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: April 03, 2024

Expires: April 02, 2025

Activities

Adjuvant CDK Inhibitors for EBC
Integrating Adjuvant CDK4/6 Inhibitors Into Care of Patients With HR-Positive/HER2-Negative Early-Stage Breast Cancer
Text Module
Congratulations: You achieved a completion on 04/09/2022

Released: May 01, 2024

Expires: April 30, 2025

BRCA Testing and Targeting in EBC
Germline BRCA Testing and Targeting in HER2-Negative Early-Stage Breast Cancer
Text Module
Congratulations: You achieved a completion on 04/09/2022

Released: May 07, 2024

Expires: May 06, 2025

Faculty

cover img faculity

Tanya Gupta, MD

Clinical Assistant Professor
Breast Oncology
Stanford Healthcare
Palo Alto, California

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC in partnership with Breastcancer.org

Supporters

Supported by educational grants from AstraZeneca, Merck Sharp & Dohme, LLC, and Novartis Pharmaceuticals Corporation.

AstraZeneca

Merck Sharp & Dohme, LLC

Novartis Pharmaceuticals Corporation

Partners

Breastcancer.org

ProCE Banner